The pharmacokinetic and pharmacodynamic properties of vancomycin (Q36328971)

13 August 2017

1 reference

title

The pharmacokinetic and pharmacodynamic properties of vancomycin (English)

1 reference

13 August 2017

1 reference

1 reference

1 reference

Michael J Rybak

1

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 January 2006

1 reference

Clinical Infectious Diseases

13 August 2017

published in

1 reference

13 August 2017

volume

42 Suppl 1

1 reference

13 August 2017

page(s)

S35-9

1 reference

Clinical pharmacokinetics of vancomycin

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1086%2F491712

Pharmacokinetics of vancomycin in patients with various degrees of renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F491712

Vancomycin pharmacokinetics in patients with various degrees of renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F491712

Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F491712

Vancomycin pharmacokinetics in normal and morbidly obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F491712

Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F491712

Vancomycin protein binding in patients with infections caused by Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F491712

Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F491712

Penetration of vancomycin into human lung tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F491712

Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F491712

Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F491712

Effect of human serum on killing activity of vancomycin and teicoplanin against Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F491712

In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F491712

Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F491712

Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance: clinical significance and treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F491712

Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F491712

Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F491712

Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F491712

Staphylococcus aureus with Heterogeneous Resistance to Vancomycin: Epidemiology, Clinical Significance, and Critical Assessment of Diagnostic Methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F491712

Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F491712

Vancomycin enhancement of experimental tobramycin nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F491712

Nephrotoxicity of vancomycin, alone and with an aminoglycoside

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F491712

Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F491712

Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F491712

A prospective study of adverse reactions associated with vancomycin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F491712

Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F491712

An experimental study of vancomycin-induced cochlear damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F491712

Vancomycin- and erythromycin-induced hearing loss in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F491712

Protein binding of vancomycin in a patient with immunoglobulin A myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F491712

Antibiotics for gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F491712

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1086%2F491712

21 January 2018

Identifiers

DOI

10.1086/491712

1 reference

13 August 2017

1 reference